MetrioPharm develops drugs for early-intervention treatment and long-term control of chronic inflammation towards the goal of preventing diseases of aging. Our drug candidates have shown the potential to be safer and more tolerable than existing therapies. MP1032 is currently in clinical Phase II.

Products, services, technology

Compounds from the MP1000 platform are orally available small molecules with a potent anti-inflammatory activity targeting oxidative stress in immune cells.

Cooperation possibilities

Licensing, strategic partnerships, investments

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2007
  • Number of employees in Switzerland
    1-9
Key business